Study of the Effects of an Investigational Drug Compared to FDA Approved Best Available Treatment for Myelofibrosis

What we are studying

The purpose of this research study is to study the effects, good and bad, of an investigational drug and look at whether or not it can improve current therapy.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • You must have an enlarged spleen
  • Confirmed diagnosis of primary myelofibrosis
  • Currently or previously treated with ruxolitinib for at least 28 days
  • Life expectancy greater than 24 weeks
  • Non-Pregnant or nursing
  • Willing to use contraception during study treatment

What is involved

  • Complete medical history
  • Medication history within 3-months prior to screening
  • Physical exam
  • Symptoms assessment
  • Vital signs
  • Ecgs
  • Ophthalmic exams
  • Blood draws
  • Questionnaires
  • Abdominal MRIs or CT Scans approximately every 12 weeks
  • Bone marrow aspirate and biopsy at Screening
  • Week 24 and 96 (for extended treatment only)

Compensation

You will be given a voucher for parking during study related visits

Contact Information

Study Coordinator
Jennifer MacLean
Email
jemaclea@wakehealth.edu
Phone
336-713-3539
Principal Investigator
Dmitriy Berenzon, MD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.